- Hem
- Om universitetet
- Hitta person
- Andreas Hallqvist
Andreas Hallqvist
Om Andreas Hallqvist
Jag arbetar kliniskt som överläkare i onkologi vid VO Onkologi, Sahlgrenska Universitetssjukhuset, med thoraxonkologi, främst lungcancer och med neuroendokrina tumörsjukdomar. Jag disputerade 2012 men en avhandling om fulldos radiokemoterapi av Icke-småcellig lungcancer. Mina forskningsprojekt kretsar kring strålbehandling av lungcancer, synergieffekter med farmaka, biverkningar samt prediktiva faktorer för behandlingsutfall ffa vid immunterapi.
-
Pulmonary adenocarcinoma in situ and minimally invasive adenocarcinomas in European patients have less KRAS and more EGFR mutations compared to advanced
adenocarcinomas.
Jennie Petterson, Dyar Mustafa, Sashidar Bandaru, Ella Äng Eklund, Andreas Hallqvist, Volkan I. Sayin, Andréanne Gagné, Henrik Fagman, Levent Akyürek
International Journal of Molecular Sciences - 2024 -
Assessing the prognostic value of KRAS mutation combined with tumor size in stage I-II non-small cell lung cancer: a retrospective
analysis
Ella A Eklund, Ali Mourad, Clotilde Wiel, Sama I. Sayin, Henrik Fagman, Andreas Hallqvist, Volkan I. Sayin
FRONTIERS IN ONCOLOGY - 2024 -
Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung
cancer
Patrik Sundström, Nikita Dutta, William Rodin, Andreas Hallqvist, Sukanya Raghavan, Marianne Quiding-Järbrink
OncoImmunology - 2024 -
KRAS G12C Mutant Non-Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer
Registry
Johan Isaksson, Anders Berglund, Karly Louie, Linda Willen, Arash Hamidian, Anders Edsjo, Fredrik Enlund, Maria Planck, Anders Vikstrom, Mikael Johansson, Andreas Hallqvist, Gunnar Wagenius, Johan Botling
CLINICAL LUNG CANCER - 2023 -
Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [177Lu]Lu-DOTATATE
Treatment.
Jens Hemmingsson, Johanna Svensson, Andreas Hallqvist, katja Smits, Viktor Johanson, Peter Bernhardt
Journal of nuclear medicine : official publication, Society of Nuclear Medicine - 2023 -
Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung
cancer
Nikita Dutta, Anna Rohlin, Ella A Eklund, Maria K Magnusson, Frida Nilsson, Levent Akyürek, Per Torstensson, Volkan I. Sayin, Anna Lundgren, Andreas Hallqvist, Sukanya Raghavan
Frontiers in Oncology - 2023 -
Astatine-211 based radionuclide therapy: Current clinical trial
landscape
Per Albertsson, Tom Bäck, Karin Bergmark, Andreas Hallqvist, Mia Johansson, Emma Aneheim, Sture Lindegren, Chiara Timperanza, K. Smerud, Stig Palm
Frontiers in Medicine - 2023 -
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based Lu-177-DOTATATE treatment of NET
patients
A. Sundlov, K. S. Gleisner, J. Tennvall, M. Ljungberg, C. F. Warfvinge, K. Holgersson, Andreas Hallqvist, Peter Bernhardt, Johanna Svensson
European Journal of Nuclear Medicine and Molecular Imaging - 2022 -
KRAS mutations impact clinical outcome in metastatic non-small cell lung
cancer.
Ella A Eklund, Clotilde Wiel, Henrik Fagman, Levent Akyürek, Sukanya Raghavan, Jan Nyman, Andreas Hallqvist, Volkan I. Sayin
Cancers - 2022 -
Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: A Dosimetry
Rationale.
Andreas Hallqvist, Johanna Svensson, Linn Hagmarker, Ida Marin, Tobias Rydén, Jean-Mathieu Beauregard, Peter Bernhardt
Biomedicines - 2021 -
Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian
cancer
Stig Palm, Tom Bäck, Emma Aneheim, Andreas Hallqvist, Ragnar Hultborn, Lars Jacobsson, H. Jensen, Sture Lindegren, Per Albertsson
Translational Oncology - 2021 -
Analysis of early respiratory-related mortality after radiation therapy of non-small-cell lung cancer: feasibility of automatic data extraction for dose–response
studies
Louise Stervik, Niclas Pettersson, J. Scherman, C. F. Behrens, C. Ceberg, S. Engelholm, K. Gunnarsson, Andreas Hallqvist, Jan Nyman, G. F. Persson, M. Pøhl, I. Wahlstedt, I. R. Vogelius, Anna Bäck
Acta Oncologica - 2020 -
LINAC-based stereotactic radiosurgery versus hypofractionated stereotactic radiotherapy delivered in 3 or 5 fractions for vestibular schwannomas: comparative assessment from a single
institution
Linn Söderlund Diaz, Andreas Hallqvist
Journal of Neuro-Oncology - 2020 -
Immune checkpoint blockade and biomarkers of clinical response in non–small cell lung
cancer
Andreas Hallqvist, Anna Rohlin, Sukanya Raghavan
Scandinavian Journal of Immunology - 2020 -
Intraperitoneal alpha-Emitting Radioimmunotherapy with At-211 in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose
Estimations
Andreas Hallqvist, Karin Bergmark, Tom Bäck, Håkan Andersson, Pernilla Dahm-Kähler, Mia Johansson, Sture Lindegren, H. Jensen, Lars Jacobsson, Ragnar Hultborn, Stig Palm, Per Albertsson
Journal of Nuclear Medicine - 2019 -
Registry-based modelling of early mortality following radiotherapy of lung
cancer
Louise Stervik, Niclas Pettersson, Jonas Scherman, Claus Behrens, Crister Ceberg, Silke Engelholm, Gitte Persson, Mette Pohl, Andreas Hallqvist, Jan Nyman, Ivan Vogelius, Anna Bäck
Radiotherapy and Oncology. Vol. 133, Suppl. 1, S207-S208 - 2019 -
Intraperitoneal Alpha-emitting Radio Immunotherapy with Astatine-211 in Relapsed Ovarian Cancer; Long-term Follow-up with Individual Absorbed Dose
Estimations.
Andreas Hallqvist, Per Albertsson, Ragnar Hultborn, Stig Palm, Karin Bergmark, Tom Bäck, Håkan Andersson, Pernilla Dahm-Kähler, Mia Johansson, Sture Lindegren, Holger Jensen, Lars Jacobsson
Journal of Medical Imaging and Radiation Sciences - 2019 -
Estimation of Long-term Risks for Cancer Induction following Adjuvant Targeted Alpha Therapy with Curative
Intent.
Stig Palm, Andreas Hallqvist, Emma Aneheim, Tom Bäck, Mia Johansson, Ragnar Hultborn, Lars Jacobsson, Sture Lindegren, Per Albertsson
Journal of Medical Imaging and Radiation Sciences - 2019 -
Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II
trial
Andreas Hallqvist, S. Bergstrom, H. Bjorkestrand, A. M. Svard, S. Ekman, E. Lundin, Erik Holmberg, M. Johansson, S. Friesland, Jan Nyman
Lung Cancer - 2018 -
An automated Monte Carlo QC system for volumetric modulated arc therapy: Possibilities and
challenges
Roumiana Chakarova, R. Cronholm, M. Krantz, P. Andersson, Andreas Hallqvist
Physica Medica-European Journal of Medical Physics - 2018 -
Positron emission tomography and computed tomographic (PET/CT) imaging for radiation therapy planning in anal cancer: A systematic review and
meta-analysis
Per Albertsson, Charlotte Alverbratt, Ann Liljegren, Emil Björkander, Annika Strandell, Ola Samuelsson, Stig Palm, Andreas Hallqvist
Critical reviews in oncology/hematology - 2018 -
Positron emission tomography and computed tomographic imaging (PET/CT) for dose planning purposes of thoracic radiation with curative intent in lung cancer patients: A systematic review and
meta-analysis.
Andreas Hallqvist, Charlotte Alverbratt, Annika Strandell, Ola Samuelsson, Emil Björkander, Ann Liljegren, Per Albertsson
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology - 2017 -
SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I
NSCLC.
Jan Nyman, Andreas Hallqvist, Jo-Smund Lund, Odd-Terje Brustugun, Bengt Bergman, Per Bergström, Signe Friesland, Rolf Lewensohn, Erik Holmberg, Ingmar Lax
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology - 2016 -
Mutated KRAS is an independent negative prognostic factor for survival in NSCLC stage III disease treated with high-dose
radiotherapy.
Andreas Hallqvist, Fredrik Enlund, C Andersson, H Sjögren, A Hussein, Erik Holmberg, Jan Nyman
Lung Cancer International - 2012 -
Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab - Pooled results from two prospective clinical
trials.
Andreas Hallqvist, Bengt Bergman, Jan Nyman
Radiotherapy and oncology - 2012 -
Optimization of radiotherapy in locally advanced lung
cancer
Andreas Hallqvist
2011 -
Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: Satellite-A phase II study from the Swedish Lung Cancer Study
Group.
Andreas Hallqvist, G Wagenius, Hillevi Rylander, O Brodin, Erik Holmberg, B Lödén, S-B Ewers, S Bergström, G Wichardt-Johansson, K Nilsson, L Ekberg, C Sederholm, Jan Nyman
Lung cancer (Amsterdam, Netherlands) - 2011 -
How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study
Group.
Jan Nyman, S Friesland, Andreas Hallqvist, M Seke, S Bergström, L Thaning, B Lödén, C Sederholm, G Wagenius
Lung cancer (Amsterdam, Netherlands) - 2009 -
Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden,
1998-2004.
Andreas Hallqvist, Hillevi Rylander, Thomas Björk-Eriksson, Jan Nyman
Pubmed - 2007